Update - Wholesale cost of Zarxio will be 15% less than Amgen's Neupogen Biosimilars land in the US as Sandoz launches Zarxio 03-Sep-2015 By Dan Stanton Sandoz has launched Zarxio, the first biosimilar in the US, despite a last ditch effort to block the copycat version of Neupogen by Amgen.